Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzoctamine is a small molecule psychotropic drug with sedative and anxiolytic properties. Unlike most sedatives, it does not depress the respiratory system; instead, it may stimulate respiration. It is primarily used for the treatment of anxiety disorders and has demonstrated efficacy comparable to chlordiazepoxide and diazepam in clinical studies. Benzoctamine also exhibits antidepressant effects and can be used in mood disorders such as depression. Its mechanism of action involves modulation of neurotransmitters in the central nervous system—specifically decreasing serotonin (5-HT) turnover—which likely contributes to its anxiolytic effect. The drug has been shown to reduce plasma corticosteroid hormone levels associated with stress and anxiety[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzoctamine.